For example, polylactic-co-glycolic acid (PLGA) NPs with a Spleen Tyrosine kinase (SYK) pathway inhibitor have been used to target and treat macrophages in chronic liver injury induced by steatohepatitis, since SYK is a critical mediator in inflammatory pathways (203). This evidence concerns the gene SYK and digestive system neoplasm.